Y2641

Y2641, a etrahydro-β-carboline derivative, is an orally active dual RANKL/TNF-α inhibitor with Kd values of 3.984 μM and 18.59 μM for RANKL and TNF-α, respectively. Y2641 inhibits RANKL-induced osteoclastogenic and has anti-inflammatory and cartilage destruction. Y2641 can be used for study of osteoarthritis[1].

Product Specifications

UNSPSC

12352005

Target

RANKL/RANK ; TNF Receptor

Related Pathways

Apoptosis; NF-κB

Field of Research

Inflammation/Immunology

Smiles

O=C([C@@H]1CC(C2=CC=CC=C2N3)=C3C4(CN(C4)C5=CC=CC=C5)N1)NC6=C(C=CC=C6C)C

Molecular Formula

C28H28N4O

Molecular Weight

436.55

References & Citations

[1]Shao Z, et al. Identification of a RANKL/TNF-α Dual-Inhibitor as a Potential Disease-Modifying Agent for the Treatment of Knee Osteoarthritis. J Med Chem. 2025 May 22;68 (10) :10216-10237.